The Epidemiology of Uterine Leiomyosarcoma
Posted on Tuesday, December 29th, 2015 at 7:58 am by Williams Hart | Updated: Thursday, March 7th, 2019 at 5:01 pm
According to the Sarcoma Foundation of America (SFA), uterine leiomyosarcoma (LMS) is a type of rare tumor, and only about six women out of a million are diagnosed in the United States every year. Most uterine LMS are diagnosed after a hysterectomy or myomectomy. While it is almost impossible to diagnose LMS before a surgery, an MRI paired with a blood test for serum lactic dehydrogenase (LDH) may result in an accurate diagnosis.
Uterine LMS is treated with surgery, and, according to statistics from the SFA, this treatment prevents the tumor from spreading beyond the uterus in 75% of the patients. Unfortunately, LMS is aggressive; there is only a 50% chance of survival within 5 years for people whose tumor is only in the uterus.
The use of power morcellators in surgeries allegedly metastasizes cancerous cells that become leiomyosarcoma. If you think you have suffered as a result of a power morcellator, speak with our lawyers at Williams Hart to begin building your product liability case. Call us today at (713) 352-7071.